Texas 2025 - 89th Regular

Texas House Bill HCR103 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	89R16409 BPG-D
2	2	By: Simmons H.C.R. No. 103
3	3
4	4
5	5
6	6
7	7	CONCURRENT RESOLUTION
8	8	WHEREAS, Cell and gene therapies can transform the lives of
9	9	people living with rare and severe diseases that are difficult to
10	10	treat; and
11	11	WHEREAS, A rapidly growing class of one-time treatments, CGT
12	12	can correct underlying causes of such conditions as sickle cell
13	13	disease, alleviating symptoms and halting progression; these
14	14	treatments have the potential to reduce health care spending over
15	15	the long term by addressing the underlying causes of disease,
16	16	reducing the severity, and decreasing health care utilization; and
17	17	WHEREAS, The high upfront cost of these treatments makes it
18	18	difficult for state Medicaid agencies to pay for them; accordingly,
19	19	the CGT Access Model was created to improve health outcomes for
20	20	people with Medicaid by supporting agreements between states and
21	21	manufacturers that will provide for treatments within a framework
22	22	that lowers prices for states and ties payment to outcomes; and
23	23	WHEREAS, A voluntary program under the Center for Medicare
24	24	and Medicaid Innovation of the federal Centers for Medicare and
25	25	Medicaid Services, the CGT Access Model tests whether a CMS-led
26	26	approach to developing and administering outcomes-based agreements
27	27	for cell and gene therapies expands Medicaid beneficiaries' access
28	28	to innovative treatment, improves their health outcomes, and
29	29	reduces health care costs and burdens to state Medicaid programs;
30	30	under the model, CMS and pharmaceutical manufacturers would
31	31	negotiate a set of key terms, including pricing and outcome
32	32	measures, that would form the basis for individual contracts
33	33	between the manufacturer and participating states; participating
34	34	states would receive CMS technical assistance and funding; and
35	35	WHEREAS, The Texas Health and Human Services Commission has
36	36	evaluated the CGT Therapy Access Model and has applied for
37	37	admission in order to test its innovative payment and service
38	38	delivery models to reduce program expenditures while enhancing the
39	39	quality of care; and
40	40	WHEREAS, Cell and gene therapies offer potentially
41	41	life-changing benefits, and their use for Texas Medicaid patients
42	42	with rare and severe diseases holds the possibility of improving
43	43	health outcomes while lowering long-term costs to the state; now,
44	44	therefore, be it
45	45	RESOLVED, That the 89th Legislature of the State of Texas
46	46	hereby express support for the Texas Health and Human Services
47	47	Commission's application to the Cell and Gene Therapy Access Model
48	48	through the Centers for Medicare and Medicaid Services and its
49	49	Center for Medicare and Medicaid Innovation.